10X GENOMICS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - 10X GENOMICS INC
Okay. Great. We're going to kick it off. I'm Tycho Peterson from the Life Science Team. Pleased to have 10X with us. Welcome, Serge. Welcome Adam. Maybe just kick it off with a little quick recap from 3Q, just thinking a little bit about some of the momentum here as we head into next year. Obviously, new product cycle, we've got a number of things going on. So, just, yeah, what were the positives and negatives out of the quarter in the 27? Yeah, no, I like that. The biggest, probably the biggest kind of positive and continuing story of this year has been the momentum of the Terra. You know, we came into this year kind of really, really enthused about the potential of the platform. It was really fun to tell the world about it back in April. And consistently since that point, it's been like really, really fun. to be out there and just see the customer enthusiasm, which has been translating into kind of all manner of kinds of metrics in terms of order flow, in terms OFUNL, just the resonance with customers out there. So I think that continued to be, that was the big story of Q2 that continued the big, I would say, the big store of Q3. Now, you know, overlay on top of that, we always knew that once we announced Atura, there's going to be some pressure on our business when it comes to, like, existing spatial business and consumables. And coming into Q3, we kind of expected that to be the biggest pinch point. And what has been a really nice, also positive kind of development is the continued strength in the consumable in the existing business that we saw. And so a lot of the quarter played out roughly as we expected, as we communicated, but there definitely were some upsides that we so, you know, in our numbers specifically on the spatial consumables, but also just continuing enthusiasm for our data. And, of course, we also saw really nice trends continuing along on their single-cell business, keep driving reaction volume, and just overall kind of the big macro trends while there is, like, you know, the academic and government funding are still pressured. Overall, the macro environment has been trending, I would say, in our favor, kind of supported by this, you Know, continued interest in AI and also with our current slate of products and translational kind of work. And I guess, how's the early user base evolved for Terra relative to kind of your initial assumptions around high-throughput clinical, spatial labs, just talk a little bit about the evolution of the customer base. Yeah, just to be clear, it's very early, right? Like we literally told the world for the first time in April that this thing existed. No one expected it. No one could imagine that that set of capabilities was coming, was going to be available to the world. And our initial kind of go-to-market strategy, naturally, was focused on customers that were already existing Xenium instrument owners, users. The idea being that those are the people that would be most ready to ramp, to take advantage of Atera, and to kind of really spread the word and serve the rest of the ecosystem out of the gate. Now, certainly those customers have been our focus, and there's a lot of interest from existing Xenium instrument owners, but also a very large fraction of the initial orders, and even more so for the finalists, from people who are not currently owners of Xeniums. And some of them are actually new to Spatial completely. So that's been really great to see. And the breadth of interest, the breadth of applications, and the depth has been really, I would say, even in excess of our expectations. And our expectations were pretty high going into the launch. And I guess, you know, obviously still early days, but just thinking about the breadth of customers and, you Know, pull-through assumptions, maybe one for Adam, you Now, how do we think about the framework for pull-thru and when we'll get kind of more granularity there? Yeah, I hate to sound like a broken record, but it's really early. So we've just got, I mean, such a small N out there. I mean we, most of the customers so far from an order, perspective are really interested in the whole transcriptome. So we're really trying to prioritize instruments because we've got demand outstripped supply. So we've tried to make sure they're getting instruments into the hands of folks that have got projects lined up that are well-funded ready to start pulling through consumables. And we'll give more color on that when we get into Q1 and guidance. And you gave some numbers on the scalability for next year, which was helpful, I guess. Are there rate-limiting factors we need to think about to scale beyond that that are important? Yeah, yeah. So, I mean, what we've said, just to reiterate, was that we would sell 50 Aterras this year. So I just want to be clear. That doesn't mean we're at that point where we're, you know, building 50. You know, it's an ambitious target, but it's a target we feel really confident in. So as we get into Q1, I feel confident we'll be able to build 50 a quarter. maybe just as important, if not more important, is really optimizing for customer success. And so ensuring that we've got field service engineer capacity and capability to get these things installed. As you can imagine, nothing out of the ordinary, but I mean, each one of the very small end thus far has had some little tweak, whether that's a site readiness issue, something else that may have happened in shipping. So really trying to work out and iron out any of those kinks, and then having field application support on-site just to make sure that the customer is up and running, successful, that they've got a consumables order that's ready to go so that when we leave, you know, through telemetry, we can actually see they're running, they're successfully running the instrument. And I guess in terms of kind of expanding the user base beyond the Xenium, you know, customers, just talk about some of the leading indicators. I mean, obviously there's grant, you know, filings, but what else are you kind of tracking as you think about expanding the market? Yeah, so kind of first of all, I mean, the most direct measure is just like, okay, the customers, we're actually putting in the money and the people in the funnel. And like I said earlier, there's a greater than expected fraction that are new to Xenium instruments. So that's a really encouraging sign to begin with. Then you kind of look at all the different sort of applications, right, that are being used to and coming online. So certainly AI is a big deal. I mean, we can talk a lot more about it, but in many ways, Atera is perfectly built for this new era of AI, and not by accident, right? That is kind of a core premise of the company, is to build tools that can measure biology, the right kind of biology at massive scale and high resolution. And Atera kind of perfectly fits this moment in a way that no previous spatial technology really did. And we're seeing a lot of interest, kind of at, you know, very large scale, like different institutions, whether it's kind of the consortia or companies, biotech companies, AI kind of native companies that are gearing up to use this technology. Or I kind of made a reference on our earnings call to companies that are like diagnostics companies that are sitting on large numbers of clinical samples that are really valuable samples that they now can apply this technology to extract maximum information content from and correlate it to clinical data as well. And I've been actually finding just in my personal conversation with customers, I was just, you know, one of the things you take adventure when you come out to these conferences, you go and you see customers. So I saw a few yesterday, and, you know, there's examples, you know, many, like where customers have had cohorts of samples, really precious samples that they've gotten, like an example of this customer yesterday, a breast cancer researcher who collected a large cohort, pre-treatment, on-treadment, post-treathment, and has been waiting for the right technology to come along to now analyze and has looked at many things along the way. Now, Terra kind of fits the need exactly. And we see many, many of these kinds of examples. You can translational research, kind of figuring out the huge thing now with all the new therapies coming online in oncology, figuring out mechanisms of resistance and predicting response to therapy. So all of that. And, you know, remember, too, Xenium in itself kind of was actually a really rapidly growing platform, the best platform in spatial biology and was rapidly growing. In fact, in the absence of Atera, we would be talking about this as, like, the most amazing thing ever, like probably the most prominent, the fastest growing platform out there. So Atera is coming into a market that's already growing really robustly but kind of blowing the doors off the whole thing and, I think, taking it to the whole next level. And by the way, Xenium is still growing. Consumables are up like mid-single digit, right? So were you surprised at kind of the resilience of Xeniam? Yeah, I think that maybe as Serge noted, I think it was one of the pleasant surprises in Q3. You know, we'd anticipated and built into, you know, guidance for the year because obviously we knew Atera was coming before you all did. So when we gave the, which was tricky giving annual guidance, you know back in whatever February knowing we were going to launch this thing in April. But we sort of worked our way to incorporate all that. We actually thought that the slowdown between Q2 and Q3 would be more prominent, and we had, like, mid-single-digit, if I recall. Q-on-Q growth still grew, you know, with Terra, or rather, Xenium's still had very strong growth in Q3. We would expect that to slow down. I mean, that's our anticipation. You know, it's kind of what we factored into the Q4 guide, that we wouldn't necessarily see continued sequential growth as more Terras get placed. I don't think that that's going to immediately fall off a cliff, but that's one of the things we're going to be keeping a close eye on is what does pull-through look like at those customers that now have had Xenium but also now have Atera installed. I guess going back to AI foundation models, I guess Atera versus Chromium, Perturb, Seek, how do you think about both those contributing to models, which do you thinks could be more meaningful, I guess, in the next couple of years? Yeah, that's a really good question, and certainly something we're watching carefully as the world is evolving really rapidly on that front. Perturbsic is a very powerful, very exciting application. It's interesting because the original papers came out back in 2016, and we've been waiting for a while for the application to really start taking off, and the last few years really has been. As a function of us introducing technologies, they're just a lot more scalable for single analysis, prices coming down on the sequencing side, and AI, of course, like where now you can run these massive experiments and make sense of the data, then feed it into foundation models, into kind of virtual models of biology. And we expect that this is like relative to what is going to happen in the future. We're still very much in the kind of embryonic state where, in both first principles, like the scale at which we need to run these experiments is much larger than what has been done so far, and also what we're hearing from customers, right? The biggest experiments right now are sort of in orders of millions, maybe getting to tens of millions. But if you listen to the people that are really forefront, you know, talk about hundreds of billions of kind of cells. And so, and then once, so of course Chromium has been kind of the workhorse and enabler of all of this, but going back to the very beginning and especially now, and especially with Flex Apex is something that we have been actually really pressing and kind of working with our customers to enable them. And we're seeing that in particular picking up in the biopharma, like a lot of adoption of Apex there. They're kind of investing in automation to build out and scale. As we look to the future, and I would say especially kind of watching what's been happening over the last several months since we announced Atera, we do think more and more of this kind of large-scale foundation model building will be based off of spatial data. And more and more will be kind of getting built with Atera as the foundation. And in fact, even perturbation screens, so where, you know, if you think about individual cells, dissociated cells, and doing these kinds of large-scale screens on them, as you're pushing up the scale to higher and higher levels, I think Atera will become the natural kind of technology for that as well, just because of the scale that it delivers. So still kind of relatively early days, and it's evolving rapidly, But this is one of the big updates that I've been kind of having in my head as I've been talking to customers is more and more interest in Atera, and Atera really being the kind of the workhorse of a lot of these applications in the future. And, of course, for us, kind of just economics, business-wise, it's great, right? Like, we like the business consolidating onto Atera for many reasons. And you are still seeing a double-digit reaction growth, I think, in Flex and Apex, right ? I mean, when does that – I mean because consumables are up 1% on single-cell, but you've got kind of the pricing. So just walk through the mechanics of when you kind of get through the pricing headwinds there. Yeah. So this is something, this strategy we've been communicating for quite some amount of time, right, especially over the course of the last year. We launched Flex Apex a year ago. There was a lot of pent-up demand right out of the gate last Q4. And Apex is meant to be like lower price, considerably lower price per reaction, but much more scalable. And so the whole equation has been kind of drive more volume. That naturally drives down average reaction price, especially as people are stepping down from more expensive kits. But it's driving a lot of volume. And actually the amount of volume we've been seeing is, I would say, in excess of what we had expected as we embarked on that strategy. And it's been quarter after quarter after corner. We're still, and it's a very dynamic kind of process, right? We've been, you know, sort of managing, you're pressing on that volume, but kind of managing the price at the same time. And the result is dynamic. The more you press on the apex conversion, the more it pulls down the average reaction price, the most pulls down on the top line, while people are gearing up to increase, you know, to kind of do more and then make up for that lower price point. And so we're still in that sort of dynamic kind of period where we're going through that transition. I would say another couple of quarters we expect for that to be the case. And then, you know, sort of I expect a measure of sort of equilibrium to be reached where sort of the incremental growth on APEX will contribute to the top line. But, yeah, we're still kind of in that dynamic stage. And when consumables combined can get back to double-digit growth, any time frame? Well, so overall, like the way that we're thinking now, especially with kind of what they are coming on, so strong, is kind of looking at the sum total of our consumables here, and that's what we're optimizing for the business, and feeling really strong, really, really good about where things are trending. Kind of now, and especially as we head into next year, there's a lot of momentum for the businesses. And again, you can sort of get lost a lot of the time in all the puts and takes around which product is kind of getting converted into which other product, but if you step back and just look at the amount of demand out there and momentum and the dollars that people are, like, gearing up to spend here, things are looking really, really strong. And obviously, we'll talk more about, you know, as we enter next year in terms of giving guide and all that. And maybe just touch on what you're doing with Catalyst Research Services, right? You've got, I think, over 100 customers signed up. Just talk a little bit about the strategy there and... Yeah. So this has been another kind of interesting development, too. So for us, historically, we've always been very much a product-focused company. It's all about putting products out there. We had a small service, a little bit for Xenium, to kind of do demos for customers ahead of instrument purchases. We invested in that as well for Atera with Catalyst Research Services, expanded it a bit. But the amount of demand has been quite dramatic for that service. And it is definitely in the service of kind of people testing things out before investing in their instruments, You know, getting some data to put into grants, to advocate within their institutions to buy an instrument themselves. But the scope, the scale, and diversity of those projects has been a really nice kind of positive, I would say, surprise to us. So we actually had to allocate a few more instruments to the service to kind of satisfy that demand, and it keeps going strong. I do think there's kind of a secular trend towards somewhat more services, where people ultimately are interested in the data and the insights, and less so necessarily of, you know, kind of getting their own sort of equipment sometimes. And so that's something that we're also kind of watching and will be, you Know, enabling as necessary as we go forward. And the customer profile there is mostly academic. I mean, just talk a little bit about, and what has it taught you around kind of repeat usage, conversion into instrument purchases? Like, what are some of the learnings? Yeah, I mean look, so far way too early. I mean we've got a big backlog of projects we need to run through, and we're kind of gearing up. Again, there's like a lot of contention between, you know, which instruments we're going to ship to customers and which ones we're deploying internally. Like probably the most contentious sort of that whole issue of like which instruments go where is the single most contentous issue in the company right now. And very early, but the scope of projects and demand is really, really diverse. Certainly, you know, lots of academic projects, but a lot of biopharma, translational. You know, we mentioned just because it's kind of fun, Procter & Gamble is an example of a customer, just like someone that would not have expected this, you're a typical life science tools sort of target. But yeah, like a really, very nice diversity. Yeah, I think it's a great leading indicator, like yet another leading indicator for demand that's going to be coming. Obviously, we've talked about we've got lots of orders, and we're going to before the foreseeable future, we're gonna be constrained by our ability to produce and deploy the instruments. But the longer-term science, like what we're seeing from CRS, are also really positive. And I guess, yeah, just thinking a little bit about, you know, the longer-term path. I mean, talk a little about just how you think about the clinical pathway here, too. I mean pharma's a nice bridge, obviously, and there's a lot of momentum here over the next couple years. But, you now, talk about timelines, you kno, for clinical adoption, in your view, around spatial in particular. Yeah, like, I mean we see a lot potential both in single cell and spatial, you know, for single cell in the kind of model of blood-based monitoring. spatial, a lot of different applications, especially in oncology. And I think there's a huge unmet need right now. There's these new generations of therapies that are like massive numbers that are already there, that are coming, more of them coming, that are really focused on targeting expression markers. So ADCs, you know, like there's lots of other types, T cell, bispecifics, T-cell engagers, all these different drugs and all these new modalities that are meant to target cells and expression markers, right? And for these, we don't really have great diagnostics. We have one of, like IHC, that's what people run. But that's good if you have one particular question in mind, one particular drug, and you decide yes or no between the drug. But if you Have several choices, now that's no longer enough. You need an assay that can comprehensively profile multiple targets at once. And that's, by definition, is a spatial, maybe single-cell assay, right? So we know there's a huge potential. When we talk to people out there in the community, whether it's scientists or researchers, whether it's researchers or physicians clearly there is a there's a there is a big need and we see as unambiguously the future and we feel like we're also are in a good position to accelerate their future and so we're engaging with a multiple medical centers around the world building up and running clinical cohorts to generate clinical evidence to to show a kind of correlations of these spatial biomarkers with clinical outcomes. There's a lot of conviction that that's kind of the future, but no one has really run the right kinds of experiments to generate that. And so we're doing that. You know, we'll talk more about it in the future. But, you know, a whole number of collaborations and things are going really well on that front. We're also building out a CLIA lab to kind of start proving out some of these concepts early on as well. We, you Know, again, when we talk, when I go out there, I talk to quite a few physicians and clinicians who tell me, it's like, well, if these tests, if the spatial single cell were available, I would send my patient samples there. And so that is part, again, early days, but I think there's huge potential there. And I think we're in a unique position to really kind of accelerate the arrival of that future. So I guess is the strategy in opening a CLIA lab on running LDTs or supporting translational biomarker programs for your partners? At this stage, kind of first step is actually an LDT to enable, because we have this demand that's coming at us. And like, for one, it's just like that service kind of needs to exist out there. And, you know, and we'll take it from there and probably scale up as we go forward. And, yeah, I think, you Know, one of the things we hear is just clinical adoption, you know. For spatial gated by lack of standardization analytics, workflow integration into pathology. How do you think about the need to, you Now, develop on those fronts? Yeah. I think it's kind of interesting. So, I mean, that's one of the things that was exciting to us about Spatial from the very beginning, it kind of marries these worlds of genomics and pathology that previously kind of existed apart and had very, a lot of discomfort in sort of like overlapping and communicating. And we felt that, you know, firsthand with a lot our previous generations of products. But especially with, you know, like starting with Xenium and now with Atera, like you're really bringing these like technologically and workflow-wise, you're really bringing those worlds together. It's very much, with Atera now, you can use standard off-the-shelf slides. You do H&E on them, and then you get this, in addition to that, this insanely detailed molecular profiling for every single cell, like single molecule readout of what is going on in a format that, again, is very familiar to the world of pathology as well, right? It's these imaging-based slides. And so it very naturally expands. There's the sort of familiarity of the, you know, the workflow and the format that you see with pathologists. It extends from that, but extends into sort of these new worlds of therapeutics and that are just exploding right now in their number. The other thing that's, like, particularly exciting now, of course, with AI, you also kind of now have the means to address the problem of inference, right? Because, you Know, one thing to produce the data, the other thing is to condense all those insights into something straightforward that you can make a clinical decision based off of. And all this new AI, the progress in AI allows you, gives you the means of extracting those insights and condensing them in a really straightforward way. And then the last bit I would also point to is that with Atera, the workflow is becoming more and more straightforward. And with what we have talked about coming in the future on the platform, in terms of automation, on instrument automation, we anticipate that actually that workflow will become probably the simplest, the most straightforward workflow you have in genomics, period. I mean, literally, slide goes in, data comes out. So all of those pieces together, like, create, like a really great substrate for interface with pathology and ultimate, you know, clinical adoption. And I guess, how do you think about the competitive landscape? Obviously, there's been a fair amount of consolidation, nanostring gone, fluent gone. I means, just how do think about, I mean, your moat here. Well, our moat is always, like, build the very best products, right, and keep pushing in our R&D. And I think our history has been a great demonstration of, like – of the power of that approach. Yeah, like I feel really good where we are. I think there is – we are probably multiple generations ahead of others, whether you look at – well, any kind of product line, you look at us here. But especially when you look out at Terra, it's – there's so much innovation that has gone into it so many like across many years and of course we're not stopping here and maybe just last one 30 seconds left on on inorganic m&a just you know how do you see the opportunity set there and how much of a priority is that well like we've we've been very focused making sure that our like from the fundamentals of our business are really sound we we put a lot of focus on efficiency, especially last year, but since then as well, to kind of make sure the business is operating really well. Our P&L looks really good, and we've generated close to $100 million of cash in the last 12 months. So we're in a really good position. We've got the balance sheet to take advantage of potential opportunities if they come along. But for us, it's always like it's got to be a really Good Strategic Rationale for making moves and if there's something out there that makes sense given the strategy, we'll take advantage of it as we've done in the past. Great. We'll leave it at that. Thanks. Thank you. Stay well.
- Company
- 10X GENOMICS INC
- Keywords
- 10X GENOMICS INC